Innovative Approaches to Diabetes Management Highlighted at ATTD 2026

At the ATTD 2026 conference held in Barcelona, the integration of artificial intelligence (AI) into diabetes management has taken center stage, fundamentally changing the care landscape for patients with diabetes. With continuous glucose monitoring (CGM) now recognized as a standard practice, the dialogue is shifting from simple data collection to the effective utilization of that data in clinical settings. The event has showcased how technology is enhancing patient education and prompting behavioral changes among those affected by diabetes.

The discussions during the conference did not view CGM merely as a passive monitoring tool. Instead, emphasis was placed on its pivotal role in educating patients about their glucose levels and how daily choices influence those outcomes. The consensus emerging from the symposium suggests that the clinical value lies not only in obtaining accurate readings but also in empowering patients to understand the relationship between their daily activities and glucose fluctuations.

AI Integration Through GS3

SIBIONICS presented its GS3 system as a prime example of AI integration in routine diabetes management. This innovative system incorporates AI-assisted voice recording, allowing users to log their meals, physical activities, and medication intake through natural speech. This recorded information is then structured into analyzable health data.

Moreover, the AI-driven analysis of meals examines the connection between dietary intake and subsequent glucose responses, while multi-day pattern recognition highlights recurring hyperglycemic events and their potential triggers. These functionalities aim to provide context to glucose variability, rather than presenting isolated data points.

Healthcare professionals including clinicians and diabetes educators noted that simplifying data entry and interpretation could reduce patient burden and potentially enhance treatment adherence. By translating glucose data into understandable cause-and-effect narratives, such tools can support more effective self-management and improve communication between patients and healthcare providers.

Continuous Keton Monitoring and Multimodal Approaches

The discussions also touched on the application of continuous ketone monitoring (CKM), particularly for individuals using SGLT-2 inhibitors. CKM can provide additional layers of insight into metabolic status, complementing CGM by tracking ketone dynamics.

Field observations suggest that correlating glucose and ketone data can unveil patterns not detectable through the isolated monitoring of individual parameters. This integrated approach holds promise for early risk detection and the development of more personalized therapeutic strategies.

Recognizing Scientific Excellence and Global Competence

The symposium was chaired by prominent figures in the field, including Prof. Lutz Heinemann from Germany and Dr. Federico Bertuzzi from Italy, both widely respected for their contributions to diabetes technology and clinical practice. The agenda also featured presentations from internationally renowned experts, such as Dr. Talita Trevisan from Brazil, who shared insights into real-world evidence of CGM effectiveness; Dr. Hande Turan from Turkey, who discussed CGM accuracy in pediatric type 1 diabetes; Dr. Ahmad Haidar from Canada, who presented findings on CKM in SGLT-2 users; and Dr. Wei Qiang from China, who introduced next-generation AI-enhanced CGM approaches.

These sessions represented a multidisciplinary viewpoint, encompassing clinical research, real-world evidence, and new technologies, reflecting ongoing advancements in diabetes care. As diabetes management continues to evolve, the integration of AI and continuous monitoring tools will likely play a transformative role in enhancing patient outcomes and informing clinical practices.